PARP inhibition promotes endothelial-like traits in melanoma cells and modulates pericyte coverage dynamics during vasculogenic mimicry
Metadata
Show full item recordAuthor
Fernández Cortés, Mónica; Delgado Bellido, Daniel; Bermúdez Jiménez, Eloísa; O'Valle Ravassa, Francisco Javier; García Díaz, Ángel; Oliver, Francisco JavierEditorial
Wiley
Materia
Vasculogenic mimicry Tumor vasculature PARP inhibitors Olaparib Melanoma Pericytes
Date
2023-01-04Referencia bibliográfica
Fernández-Cortés, M... [et al.] (2023), PARP inhibition promotes endothelial-like traits in melanoma cells and modulates pericyte coverage dynamics during vasculogenic mimicry. J. Pathol., 259: 318-330. [https://doi.org/10.1002/path.6043]
Sponsorship
Spanish Government Ministry of Science and Innovation, Spain (MICINN) Spanish Government SAF2015-70520-R RTI2018-098968-B-I00 RTICC RD12/0036/0026; CIBER Cancer ISCIII CB16/12/00421; Junta de Andalucia PY20_01179; Fundacion Domingo MartinezAbstract
Vasculogenic mimicry (VM) describes the ability of highly aggressive tumor cells to develop pseudovascular structures
without the participation of endothelial cells. PARP1 is implicated in the activation of hypoxia-inducible factors,
which are crucial in tumor neovascularization. We have explored the role of hypoxia and PARP inhibition in VM.
In uveal melanoma xenografts, the PARP inhibitor olaparib improved in vivo pericyte coverage specifically of VM
channels. This was concomitant with reduced metastasis in olaparib-treated VM+ tumors. PARP inhibition and hypoxia
modulated melanoma tube formation in vitro, inducing a more sparse and regular tubular architecture. Wholetranscriptome
profiling revealed that olaparib treatment under hypoxic conditions modulated the expression of
genes implicated in vasculogenesis during tube formation, enhancing the endothelial-like phenotype of VM+ uveal
melanoma cells. PARP inhibition, especially during hypoxia, upregulated PDGFβ, which is essential for pericyte
recruitment. Our study indicates that PARP inhibitors may enhance the endothelial characteristics of VM+ cells,
modulate pericyte coverage, and reduce metastatic spread in VM+ melanoma.